## **Errata**

## December 13, 2010

The Technology Assessment "Bone Morphogenetic Protein: The State of the Evidence of On-Label and Off-Label Use," dated December 13, 2010 includes three minor corrections to the original version from dated August 6, 2010. First, on page 44, line 4, referring to infections in association with Gustilo-Anderson type III fractures, the text in parentheses now reads "(24 percent compared with 44 percent)". This was a simple typographical error.

On page 50, Table 22, the USPSTF study quality now reads "4 FAIR", rather than "3 FAIR". This was a typographical error.

On page 51, Table 23, referring to the Dawson et al, 2009 article, the numbers in the ODI mean point score increase column now read "28" for the BMP2/BCP group, and "23" for the ICBG group. The numbers in the leg pain mean point score column now read "9.3" for the BMP2/BCP group, and "7.2" for the ICBG group. These represent typographical and transcriptional errors.

None of these minor corrections will have any impact on the findings of the assessment, as they were accounted for in the GRADE synthesis and conclusions.